Show Summary Details
Page of

Spondyloarthropathies 

Spondyloarthropathies
Chapter:
Spondyloarthropathies
Author(s):

Carmel Stober

and Hill Gaston

DOI:
10.1093/med/9780199688371.003.0003
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 23 April 2021

This collection of papers may differ from those chosen in other forms of arthritis in having a paucity of papers on treatment and, in particular, no classic double-blind placebo-controlled clinical trials. The single trial included, by Brandt et al., was a small (tiny) open-label trial but nevertheless established beyond reasonable doubt the major role of tumour necrosis factor inhibition in the treatment of ankylosing spondylitis—later confirmed in formal trials and extended to other forms of spondyloarthritis (SpA). Arguably, this has been the only significant advance in treatment of SpA in the last three to four decades (discounting the necessary testing of various novel non-steroidal anti-inflammatory drugs over the years). Many other biologics and small molecules are of course being investigated currently for SpA treatment. However, while this is an exciting time in SpA treatment research, it has not yet generated any “classic” papers.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.